Pierre Fabre to commercialize and distribute the first approved allogeneic T-cell immunotherapy in Europe Following transfer of the European Commission marketing authorization from Atara Biotherapeutics, Pierre Fabre is to lead launch and commercialization activities for Ebvallo® (tabelecleucel) in Europe The french group Pierre Fabre and Atara Biotherapeutics, a californian biotech…..
How to increase the number of European-based ATMP clinical trials? The latest report published by the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader advanced therapies sector, shows that Europe has become less competitive than other regions in attracting new advanced…..